Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects

Completed · Phase 2

Conditions studied: Polio Immunity

In brief

The purpose of this study is to determine whether a lower dose of inactivated polio vaccine (IPV) injected into the skin (intradermal administration) can work equally well or better than the standard dose injected into the muscle (intramuscular administration). There are more immune cells in the skin than in the muscle, and other vaccines have been shown to require a lower dose when administered intradermally. The study is being done in participants infected with HIV because HIV-infected people are known to respond less well to vaccines than other groups, so it is particularly important to know if IPV might work better in HIV-infected people if administered intradermally. If it is possible to lower the dose of IPV by intradermal administration, this would make inactivated polio vaccine more affordable in the developing countries where it is most needed

Key facts

Study ID: NCT01686503
Run by: Eastern Virginia Medical School
People needed: 231
Starts: 2012-09-01
Expected to finish: 2013-08-01
Last updated by the study team: 2015-02-05

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

documented HIV infection
age of at least 18 years old
HIV viral load <400 on the most recent test

You may not qualify if…

current acute moderate to severe illness (demonstrated by fever over 100.4 Fahrenheit, shortness of breath, altered mental status, or by judgment of the primary clinician)
current pregnancy
history of allergic reaction to a polio shot,
history of a life-threatening allergic reaction to neomycin, streptomycin, or polymyxin B

Where it is running

C3ID Clinic, Eastern Virginia Medical School — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.